ArticleThe Journal of rheumatology2013
Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
Article in The Journal of rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Association Between MTHFR C677T Gene Polymorphism and Repeated Pregnancy Loss in Arabic Countries: a Systematic Review and Meta-Analysis.Reproductive sciences (Thousand Oaks, Calif.) · 2023Pooled it
- Associations of methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms with genetic susceptibility to rheumatoid arthritis: a meta-analysis.Clinical rheumatology · 2017Pooled it
- Adipokines and Associations With Incident Osteoporotic Fracture in Patients With Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Elevations in adipocytokines and mortality in rheumatoid arthritis.Rheumatology (Oxford, England) · 2022Article
- Adipocytokines and achievement of low disease activity in rheumatoid arthritis.Seminars in arthritis and rheumatism · 2022Article
- Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis.Scientific reports · 2022Article
- Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis.Frontiers in cardiovascular medicine · 2022Review
- Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.Annals of the rheumatic diseases · 2021Article
- Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.Annals of the rheumatic diseases · 2021Article
- Ethnic Disparities in Atherosclerotic Cardiovascular Disease Incidence and Prevalence Among Rheumatoid Arthritis Patients in the United States: a Systematic Review.ACR open rheumatology · 2020Article
- Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis.Arthritis research & therapy · 2020Article
- Quality of available internet information regarding IV sedation for dental treatment.British dental journal · 2020Article
- Obesity, Weight Loss, and Progression of Disability in Rheumatoid Arthritis.Arthritis care & research · 2018Article
- Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2018Article
- Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.BMJ (Clinical research ed.) · 2018Review
- Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment.Cardiology research · 2016Article
- Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Predictors of longterm changes in body mass index in rheumatoid arthritis.The Journal of rheumatology · 2015Article
- Association of a methylene tetrahydrofolate reductase C677T polymorphism with several blood chemical levels in a Chinese population.Genetic testing and molecular biomarkers · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
objectiveC677T and A1298C polymorphisms in the enzyme methylenetetrahydrofolate reductase (MTHFR) have been associated with increased cardiovascular (CV) events in non-rheumatoid arthritis (RA) populations. We investigated potential associations of MTHFR polymorphisms and use of methotrexate (MTX) with time-to-CV event in data from the Veterans Affairs Rheumatoid Arthritis (VARA) registry.
methodsVARA participants were genotyped for MTHFR polymorphisms. Variables included demographic information, baseline comorbidities, RA duration, autoantibody status, and disease activity. Patients' comorbidities and outcome variables were defined using International Classification of Diseases-9 and Current Procedural Terminology codes. The combined CV event outcome included myocardial infarction (MI), percutaneous coronary intervention, coronary artery bypass graft surgery, and stroke. Cox proportional hazards regression was used to model the time-to-CV event.
resultsData were available for 1047 subjects. Post-enrollment CV events occurred in 97 patients (9.26%). Although there was a trend toward reduced risk of CV events, MTHFR polymorphisms were not significantly associated with time-to-CV event. Time-to-CV event was associated with prior stroke (HR 2.01, 95% CI 1.03-3.90), prior MI (HR 1.70, 95% CI 1.06-2.71), hyperlipidemia (HR 1.57, 95% CI 1.01-2.43), and increased modified Charlson-Deyo index (HR 1.23, 95% CI 1.13-1.34). MTX use (HR 0.66, 95% CI 0.44-0.99) and increasing education (HR 0.87, 95% CI 0.80-0.95) were associated with a lower risk for CV events.
conclusionAlthough MTHFR polymorphisms were previously associated with CV events in non-RA populations, we found only a trend toward decreased association with CV events in RA. Traditional risk factors conferred substantial CV risk, while MTX use and increasing years of education were protective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.